(Q45153094)

10 December 2017

0 references

RANK ligand inhibition in bone metastatic cancer and risk of osteonecrosis of the jaw (ONJ): non bis in idem? (English)

1 reference

10 December 2017

1

1 reference

10 December 2017

Kristien Wouters

2

1 reference

10 December 2017

Manon T Huizing

series ordinal

3

1 reference

10 December 2017

Jan B Vermorken

series ordinal

4

1 reference

10 December 2017

publication date

4 January 2011

1 reference

Supportive Care in Cancer

10 December 2017

published in

1 reference

10 December 2017

volume

19

1 reference

10 December 2017

issue

12

1 reference

10 December 2017

page(s)

2035-2040

1 reference

Bisphosphonates and osteonecrosis of the jaw: cause and effect or a post hoc fallacy?

10 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00520-010-1061-0

Bisphosphonates in oncology: rising stars or fallen heroes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-010-1061-0

Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-010-1061-0

Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-010-1061-0

A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-010-1061-0

Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-010-1061-0

Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-010-1061-0

U.S. Food and Drug Administration drug approval summaries: imatinib mesylate, mesna tablets, and zoledronic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-010-1061-0

Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-010-1061-0

Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-010-1061-0

Remodeling dynamics in the alveolar process in skeletally mature dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-010-1061-0

Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-010-1061-0

Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-010-1061-0

Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-010-1061-0

Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-010-1061-0

Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-010-1061-0

Osteonecrosis of the jaw related to the use of bisphosphonates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-010-1061-0

Initial experience with conservative treatment in cancer patients with osteonecrosis of the jaw (ONJ) and predictors of outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-010-1061-0

Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-010-1061-0

American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21203781

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21203781

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S00520-010-1061-0

1 reference

release_gbg5n45singljn2n5nfbt7zlqu

10 December 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/gbg5n45singljn2n5nfbt7zlqu

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference